Simvastatin prevents TFGB1 induced SMAD2/3 phosphorylation in human ventricular fibroblasts: involvement of protein phosphatase

Authors

Farhan Rizvi, Advocate Aurora HealthFollow
Ramail Siddiqui, Advocate Aurora HealthFollow
Alessandra DeFranco, Advocate Aurora HealthFollow
Hao Xu
Larisa Emelyanova, Advocate Aurora HealthFollow
Gracious R. Ross, Sheikh Khalifa bin Hamad Al Thani Center for Integrative Research on Cardiovascular Aging, Aurora Research Institute, Advocate Aurora HealthFollow
Yang Shi, Advocate Aurora HealthFollow
Ekhson Holmuhamedov, Advocate Aurora HealthFollow
A Jamil Tajik, Advocate Aurora HealthFollow
Arshad Jahangir, Advocate Aurora HealthFollow

Recommended Citation

Rizvi F, Siddiqui R, DeFranco A, Xu H, Emelyanova L, Ross G, Shi Y, Holmuhamedov E, Tajik A, Jahangir A. Simvastatin prevents TFGB1 induced SMAD2/3 phosphorylation in human ventricular fibroblasts: involvement of protein phosphatase. Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.

Affiliations

Center for Integrative Research on Cardiovascular Aging, Aurora Research Institute, Aurora Cardiovascular Services, Aurora Health Care

Presentation Notes

Poster presented at: Aurora Scientific Day; May 25, 2016; Milwaukee, WI.

Abstract

Conclusions: Simvastatin prevents the pro-fibrotic cytokine, TGF-B1 induced differentiation of fibroblasts to myofibroblasts by SMAD2/3 dephosphorylation via phosphatases: PPM1A and PP2A.

The involvement of PPM1A and PP2A in the anti-fibrotic effect of simvastatin reveals novel signaling mediators that may be selectively targeted for prevention of myocardial injury-induced ventricular fibrosis and heart failure.

Document Type

Poster